Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on Grillo Insights’s Substack by Eric García. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $116.11 as of April 15th. TMDX’s trailing and forward P/E were 23.84 and 46.51 respectively according to Yahoo Finance.
hywards/Shutterstock.com
TransMedics Group, Inc. TMDX is a leading innovator in organ preservation technology, centered around its Organ Care System, a portable platform designed to maintain and transport organs for transplantation across heart, lung, liver, and kidney procedures. The company operates a hybrid model combining device sales with recurring revenue through its National Organ Care System Program, positioning it to benefit from both capital equipment adoption and ongoing service utilization.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Having already facilitated over 10,000 organ transplants, TransMedics is targeting 20,000–30,000 transplants annually by 2030, driven by expanding clinical indications and increasing adoption across transplant centers. Significant growth catalysts include ongoing Phase 3 heart and lung clinical trials, with results expected in 2026, which could unlock substantially larger addressable markets, alongside the anticipated launch of its next-generation kidney Organ Care System platform in early 2027.
International expansion into Europe, the Middle East, and Australia further enhances its long-term growth runway. The recent acquisition of OrganOx by Terumo has validated the organ preservation category, yet TransMedics maintains a competitive edge through superior liver outcomes and advancing heart and lung capabilities supported by proprietary technology.
While the stock has recently recovered post-earnings and may appear fairly valued in the near term, continued clinical outperformance and execution could drive meaningful upside. Positive trial results in 2026 have the potential to catalyze new all-time highs, reinforcing TransMedics’ position as a high-quality growth compounder in a rapidly evolving healthcare segment with a 2026 price target of $164.
Previously, we covered a bullish thesis on TransMedics Group, Inc. by Oliver Wealth in May 2025, which highlighted the company’s disruptive Organ Care System, strong growth trajectory, and valuation reset after a sharp decline. TransMedics Group, Inc.’s stock price has appreciated by approximately 21.18% since our coverage. Eric García shares a similar view but emphasizes clinical catalysts and expansion.
TransMedics Group, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held TMDX at the end of the fourth quarter which was 34 in the previous quarter. While we acknowledge the risk and potential of TMDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
